OxyContin's Planned Epidemiological Study Program
You may also be interested in...
Abuse Reduction Claim In Opioid Label Will Be Difficult To Attain
FDA draft guidance says there is no clear epidemiologic strategy for gathering the data to demonstrate that has reduced abuse; the agency outlines four possible kinds of abuse deterrence claims, three of which can be obtained through pre-market studies.
Pfizer Will Study Oxecta Abuse/Misuse Potential Post-Market
FDA okays the opioid, which contains abuse-resistant components, with labeling about a study that found the drug less likeable than immediate-release oxycodone.
Pfizer Will Study Oxecta Abuse/Misuse Potential Post-Market
FDA okays the opioid, which contains abuse-resistant components, with labeling about a study that found the drug less likeable than immediate-release oxycodone.